Relapsed/refractory Langerhans histiocytosis
Conditions
Interventions
experimental group:CD207 - CAR - T cells
Sponsors
Beijing GoBroad Boren Hospital
Eligibility
Sex/Gender
All
Age
3 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. For patients diagnosed with Langerhans histiocytosis, relapse during chemotherapy, or primary drug resistance, or relapse after drug withdrawal (stop all scheduled chemotherapy courses), and complete remission cannot be achieved after 1 course of chemotherapy; 2. Aged 3-65 years; 3. Predicted survival > 12 weeks; 4. ECOG physical status score 0-1 or KPS score > 80; 5. Adequate venous access for simple or intravenous blood collection and no other contraindications for blood cell separation; 6. WBC>=2.5x10^9/L, LY>=0.7x10^9/L, LY%>=15%; 7. Serum creatinine <=2.0mg/dL (176.8µmol/L); 8. ALT and AST<=2.5 ULN; 9. Serum total bilirubin <=2.0mg/dL (34.2µmol/L); 10. PT: INR < 1.7 or PT longer than normal < 4s; 11. The patient is self-aware, or the patient signs a power of attorney to authorize the entruster, and the guardian of the child patient signs an informed consent letter to join the study.
Exclusion criteria
Exclusion criteria: 1. Transduction-positive T lymphocytes were 300mg/d; Clopidogrel, dose > 75mg/d). 18. Radiotherapy was performed within 4 weeks prior to study initiation (blood collection). 19. Uncontrolled symptoms or other diseases include, but are not limited to, infections, congestive heart failure, unstable angina, arrhythmias, psychosis, or those that pose an unpredictable risk in the opinion of the attending physician. 20. Patients with severe acute allergic reactions. 21. Patients participating in other clinical trials. 22. The researchers did not consider clinical participants appropriate for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective response rate;Incidence and severity of adverse reactions; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival; | — |
Countries
China
Contacts
Public ContactLi Zhihui
Beijing GoBroad Boren Hospital
Outcome results
None listed